-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving Average of $0.81
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving Average of $0.81
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.81 and traded as high as $0.85. ProQR Therapeutics shares last traded at $0.84, with a volume of 436,743 shares.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, May 9th. Chardan Capital cut shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, August 12th. Cantor Fitzgerald cut shares of ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, August 15th. Raymond James upgraded shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target on the stock in a report on Friday, August 12th. Finally, HC Wainwright cut their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a report on Monday, May 9th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $5.00.
Get ProQR Therapeutics alerts:ProQR Therapeutics Stock Up 2.3 %
The company has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.98. The company has a market cap of $59.61 million, a P/E ratio of -0.84 and a beta of 0.80. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The business had revenue of $1.09 million for the quarter, compared to the consensus estimate of $1.21 million. ProQR Therapeutics had a negative return on equity of 57.34% and a negative net margin of 1,859.05%. On average, equities analysts anticipate that ProQR Therapeutics will post -0.81 EPS for the current year.Institutional Trading of ProQR Therapeutics
Several institutional investors have recently bought and sold shares of PRQR. ProShare Advisors LLC purchased a new position in ProQR Therapeutics during the fourth quarter worth approximately $80,000. Coastal Bridge Advisors LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $85,000. Corton Capital Inc. acquired a new position in ProQR Therapeutics during the 4th quarter worth $280,000. Virtu Financial LLC acquired a new position in ProQR Therapeutics during the 2nd quarter worth $48,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ProQR Therapeutics by 82.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,973 shares of the biopharmaceutical company's stock worth $560,000 after acquiring an additional 31,614 shares in the last quarter.
About ProQR Therapeutics
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Featured Articles
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- PENN Entertainment Stock is Reset and Ready to Rebound
- 3 Payroll Software Makers Set For Growth In 2023
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.81 and traded as high as $0.85. ProQR Therapeutics shares last traded at $0.84, with a volume of 436,743 shares.
在周三的交易中,ProQR治疗公司(纳斯达克:PRQR-GET评级)超过了50日移动平均线。该股的50日移动均线为0.81美元,最高交易价格为0.85美元。ProQR治疗公司的股票最后交易价格为0.84美元,成交量为436,743股。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities research analysts have commented on the stock. StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, May 9th. Chardan Capital cut shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, August 12th. Cantor Fitzgerald cut shares of ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, August 15th. Raymond James upgraded shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target on the stock in a report on Friday, August 12th. Finally, HC Wainwright cut their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a report on Monday, May 9th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $5.00.
几位股票研究分析师对该股发表了评论。在5月9日(星期一)的一份报告中,StockNews.com将ProQR治疗公司的股票评级从“卖出”上调至“持有”。在8月12日星期五的一份研究报告中,Chardan Capital将ProQR治疗公司的股票评级从“买入”下调至“中性”。在8月15日星期一的一份报告中,坎托·菲茨杰拉德将ProQR治疗公司的股票评级从“增持”下调至“中性”。Raymond James在8月12日(星期五)的一份报告中将ProQR治疗公司的股票评级从“市场表现”上调至“跑赢大盘”,并为该股设定了2.00美元的目标价。最后,在5月9日星期一的一份报告中,HC Wainwright将ProQR治疗公司的股票目标价从4.00美元下调至2.00美元。五名投资分析师对该股的评级为持有,四名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该股的共识评级为持有,共识目标价为5美元。
ProQR Therapeutics Stock Up 2.3 %
ProQR治疗公司股票上涨2.3%
The company has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.98. The company has a market cap of $59.61 million, a P/E ratio of -0.84 and a beta of 0.80. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43.
该公司的50日简单移动均线切入位在0.81美元,200日简单移动均线切入位在0.98美元。该公司市值为5961万美元,市盈率为-0.84,贝塔系数为0.80。该公司的流动比率为5.93,速动比率为5.93,债务权益比率为0.43。
Institutional Trading of ProQR Therapeutics
ProQR治疗药物的制度性交易
Several institutional investors have recently bought and sold shares of PRQR. ProShare Advisors LLC purchased a new position in ProQR Therapeutics during the fourth quarter worth approximately $80,000. Coastal Bridge Advisors LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $85,000. Corton Capital Inc. acquired a new position in ProQR Therapeutics during the 4th quarter worth $280,000. Virtu Financial LLC acquired a new position in ProQR Therapeutics during the 2nd quarter worth $48,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ProQR Therapeutics by 82.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,973 shares of the biopharmaceutical company's stock worth $560,000 after acquiring an additional 31,614 shares in the last quarter.
几家机构投资者最近买卖了PRQR的股票。ProShare Advisors LLC在第四季度购买了ProQR治疗公司的一个新头寸,价值约8万美元。Coastal Bridge Advisors LLC在第四季度收购了ProQR治疗公司价值8.5万美元的新股份。Corton Capital Inc.在第四季度收购了ProQR治疗公司的一个新头寸,价值28万美元。Virtu Financial LLC在第二季度收购了ProQR治疗公司的一个新头寸,价值4.8万美元。最后,康纳·克拉克和伦恩投资管理有限公司在第四季度将其在ProQR治疗公司的股票持有量增加了82.4%。康纳-克拉克-伦恩投资管理有限公司目前持有69,973股这家生物制药公司的股票,价值560,000美元,该公司在上个季度增持了31,614股。
About ProQR Therapeutics
关于ProQR治疗公司
(Get Rating)
(获取评级)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物制药公司,致力于发现和开发基于RNA的治疗遗传疾病的疗法。它主要开发正处于II/III期临床试验的sepofarsen,用于治疗Leber先天性黑发10病的照明试验;以及正在进行II/III期临床试验的ultevursen,用于治疗USH2A介导的视网膜色素变性和USHER综合征。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- PENN Entertainment Stock is Reset and Ready to Rebound
- 3 Payroll Software Makers Set For Growth In 2023
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
- 免费获取StockNews.com关于ProQR治疗(PRQR)的研究报告
- 宾夕法尼亚娱乐公司股票重置,准备反弹
- 3家薪资软件制造商将在2023年实现增长
- 纽约证交所股票为投资者提供多种优质选择
- ZOOM视频通信估值与现实重新接轨
- J.M.斯莫克公司证明了史泰博表现优异的原因
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProQR治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧